NCT06587061View on ClinicalTrials.gov

HRS-4642 in Combination With AG for Neoadjuvant and Adjuvant Treatment of Pancreatic Cancer

PHASE2RecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

December 3, 2024

Primary Completion Date

June 30, 2027

Study Completion Date

December 31, 2027

Conditions
Pancreatic Cancer
Interventions
DRUG

HRS-4642+AG

HRS-4642 in Combination With Gemcitabine and Albumin-bound Paclitaxel will be administrated per dose level in which the patients are assigned.

Trial Locations (1)

200025

RECRUITING

Ruijin Hospital Shanghai Jiaotong University School of Medicine, Shanghai

All Listed Sponsors
collaborator

Jiangsu HengRui Medicine Co., Ltd.

INDUSTRY

lead

Ruijin Hospital

OTHER